Results 291 to 300 of about 6,075,775 (387)

The role of small or single-institution prospective studies in thoracic research [PDF]

open access: yes, 2019
Frye, C. Corbin   +6 more
core   +1 more source

ROS‐Responsive Wedelolactone Hydrogel Promotes Intervertebral Disc Repair by Disrupting the NF‐κB–LCN2 Inflammatory Feedback Loop

open access: yesAdvanced Science, EarlyView.
A mechanically robust, ROS‐responsive hydrogel is engineered to treat intervertebral disc degeneration by targeting the NF‐κB–LCN2 inflammatory feedback loop. By delivering wedelolactone specifically within oxidative niches, this system disrupts macrophage–disc cell crosstalk.
Zimei Wu   +10 more
wiley   +1 more source

Rethinking Power Solutions for Healthcare Wearables: From Point‐of‐Care and Episodic use to Continuous Monitoring and Therapeutic Platforms

open access: yesAdvanced Energy and Sustainability Research, EarlyView.
This Perspective examines practical power solutions for wearable healthcare systems, highlighting the limits of standard batteries. It categorizes wearables into four domains—point‐of‐care diagnostics, episodic monitoring, continuous long‐term monitoring, and therapeutic platforms—and analyzes their power needs.
Seokheun Choi
wiley   +1 more source

Targeted ERAS implementation for postoperative care after Bellwether procedures in Africa: A pragmatic cluster-randomized trial from Ethiopia

open access: yes
Belachew FK   +13 more
europepmc   +1 more source

POSTOPERATIVE CARE [PDF]

open access: yesAnesthesiology, 1958
openaire   +1 more source

Combination of Ethoxybenzyl‐Diethylenetriamine Pentaacetic Acid‐Enhanced Magnetic Resonance Imaging and a Serum Biomarker Is Useful in the Diagnosis of Hepatic Sinusoidal Disorder After Chemotherapy Treatment

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
ROC analyses of APRI score, EOB‐MRI, and a combination of EOB‐MRI and APRI score for blue liver. ABSTRACT Aim Sinusoidal obstruction syndrome (SOS), also known as “blue liver (BL),” is a common hepatic injury following oxaliplatin‐based chemotherapy in patients with colorectal liver metastases (CRLM).
Tomonari Shimagaki   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy